Science and Research

beta-Nicotinamide Adenine Dinucleotide (beta-NAD) Inhibits ATP-Dependent IL-1beta Release from Human Monocytic Cells

While interleukin-1beta (IL-1beta) is a potent pro-inflammatory cytokine essential for host defense, high systemic levels cause life-threatening inflammatory syndromes. ATP, a stimulus of IL-1beta maturation, is released from damaged cells along with beta-nicotinamide adenine dinucleotide (beta-NAD). Here, we tested the hypothesis that beta-NAD controls ATP-signaling and, hence, IL-1beta release. Lipopolysaccharide-primed monocytic U937 cells and primary human mononuclear leukocytes were stimulated with 2'(3')-O-(4-benzoyl-benzoyl)ATP trieethylammonium salt (BzATP), a P2X7 receptor agonist, in the presence or absence of beta-NAD. IL-1beta was measured in cell culture supernatants. The roles of P2Y receptors, nicotinic acetylcholine receptors (nAChRs), and Ca(2+)-independent phospholipase A2 (iPLA2beta, PLA2G6) were investigated using specific inhibitors and gene-silencing. Exogenous beta-NAD signaled via P2Y receptors and dose-dependently (IC50 = 15 microM) suppressed the BzATP-induced IL-1beta release. Signaling involved iPLA2beta, release of a soluble mediator, and nAChR subunit alpha9. Patch-clamp experiments revealed that beta-NAD inhibited BzATP-induced ion currents. In conclusion, we describe a novel triple membrane-passing signaling cascade triggered by extracellular beta-NAD that suppresses ATP-induced release of IL-1beta by monocytic cells. This cascade links activation of P2Y receptors to non-canonical metabotropic functions of nAChRs that inhibit P2X7 receptor function. The biomedical relevance of this mechanism might be the control of trauma-associated systemic inflammation.

  • Hiller, S. D.
  • Heldmann, S.
  • Richter, K.
  • Jurastow, I.
  • Kullmar, M.
  • Hecker, A.
  • Wilker, S.
  • Fuchs-Moll, G.
  • Manzini, I.
  • Schmalzing, G.
  • Kummer, W.
  • Padberg, W.
  • McIntosh, J. M.
  • Damm, J.
  • Zakrzewicz, A.
  • Grau, V.

Keywords

  • Adenosine Triphosphate/metabolism
  • Cell Line, Tumor
  • Cells, Cultured
  • Humans
  • Interleukin-1beta/*metabolism
  • Lipopolysaccharides/pharmacology
  • Monocytes/*metabolism
  • NAD/*pharmacology
  • Nicotinic Antagonists/pharmacology
  • Phospholipase A2 Inhibitors/pharmacology
  • Phospholipases A2/genetics/metabolism
  • Purinergic P2Y Receptor Antagonists/pharmacology
  • Receptors, Nicotinic/genetics/metabolism
  • Receptors, Purinergic P2Y/genetics/metabolism
  • Chrna10
  • Chrna7
  • Chrna9
  • P2ry1
  • P2ry11
  • Pla2g6
  • U937 cells
  • iPLA2beta
  • inflammasome
  • interleukin-1beta
  • monocyte
  • beta-NAD
  • beta-nicotinamide adenine dinucleotide
  • antagonists used in this study. All other authors declare no conflict of
  • interest.
Publication details
DOI: 10.3390/ijms19041126
Journal: International journal of molecular sciences
Number: 4
Work Type: Original
Location: UGMLC
Disease Area: PALI
Partner / Member: JLU
Access-Number: 29642561
See publication on PubMed


chevron-down